Voluntary nationwide recall: Famotidine (Fresenius – November)

Nov. 2025Pharmacy Updates

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.

This drug is being recalled because the level of a bacteria component called endotoxin was higher than the acceptable range in one sample. Using a product with elevated endotoxin may cause nonserious reactions such as chills, change in mental status, change in breathing status, fever, increase in body temperature, shivering, and shaking. It may also cause severe reactions such as sepsis and septic shock or may lead to death.

As of Nov. 7, the nonserious reactions mentioned above were reported with one lot. There had been no reports of adverse events related to the second and third lots.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Famotidine or are experiencing any problems that may be related to receiving the product, you should stop using it and talk to your doctor.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Fresenius Kabi USA Quality Assurance at 866-716-2459. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

Voluntary nationwide recall: True Metrix (Trividia – May)

Trividia Health is recalling all True Metrix Blood Glucose Systems for an issue with the software design of the E-5 Error Code and instructions for the user in the “Messages” section of the Owner’s Booklet/System instructions for use and online labeling and help guides.
May 2026Pharmacy Updates

Community Care Behavioral Health is excited to announce this free upcoming web-based training opportunity:

A growing body of U.S. and international research demonstrates that the rapid legalization and commercialization of gambling—including online casinos and mobile sports betting platforms—are associated with significant and escalating gambling related harm. Although Pennsylvania specific prevalence data remain limited, available evidence is increasingly concerning, with gambling disorder linked to alarmingly high rates of suicide, psychiatric comorbidity, and social and financial harm. Drawing on lessons from the tobacco and opioid crises, this presentation will examine how delayed recognition and regulation can amplify population level harm, underscoring the need for earlier screening, prevention, and policy engagement. Participants will gain practical guidance on identifying patients at elevated risk, implementing evidence informed screening and diagnostic strategies, and applying current treatment approaches across the lifespan.
May 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Apr. 2026Education/Webinars